Keyword: Skyrizi

Two-year data showed the Skyrizi could provide long-term relief for psoriasis, and re-treatment after a relapse could help regain skin clearance.

AbbVie is rolling out psoriasis drug Skyrizi after an approval last month, and it's offered Humira discounts in payer negotiations to support the launch, an analyst writes.

Two of Eli Lilly's key growth drivers came up short in the first quarter, and execs faced a grilling on what they plan to do about it.

AbbVie's Humira just posted its first-ever drop in worldwide sales—and with biosimilars on the march in Europe, it's not likely to be the last.

A new investigative report outlines how AbbVie worked to keep Humira market share upon the introduction of biosimilars in the Netherlands.